R-CHOP with or without bevacizumab in patients with previously untreated diffuse large B-cell lymphoma: final MAIN study outcomes

Vascular endothelial growth factor is involved in lymphoma growth, suggesting a potential role for anti-vascular endothelial growth factor therapies in hematologic malignancies. In this phase III study, patients with CD20-positive diffuse large B-cell lymphoma were randomized to rituximab, cyclophos...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Seymour, John F., Pfreundschuh, Michael, Trnĕný, Marek, Sehn, Laurie H., Catalano, John, Csinady, Eva, Moore, Nicola, Coiffier, Bertrand
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Ferrata Storti Foundation 2014
Gaiak:
Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4116833/
https://ncbi.nlm.nih.gov/pubmed/24895339
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2013.100818
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak